Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label study of selumetinib alone and with docetaxel in Japanese patients with advanced solid tumors and NSCLC
jRCT2080221837Phase 1
- Sponsor
- AstraZeneca
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selumetinib in Non-hematologic malignancy and non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Primary safety and tolerability of selumetinib alone and in combination with docetaxel.
02
Drugs
selumetinib
03
Conditions
Non-hematologic malignancynon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080221837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221837.